Lazar David E. 4
4 · Cyclacel Pharmaceuticals, Inc. · Filed Feb 10, 2025
Insider Transaction Report
Form 4
Lazar David E.
DirectorChief Executive Officer
Transactions
- Award
Series D Convertible Preferred Stock
2025-02-06+2,100,000→ 2,100,000 totalFrom: 2025-02-06→ Common Stock (231,000,000 underlying)
Holdings
- 1,000,000
Series C Convertible Preferred Stock
From: 2025-01-06→ Common Stock (2,650,000 underlying)
Footnotes (6)
- [F1]On January 2, 2025, David E. Lazar (the "Reporting Person") and Cyclacel Pharmaceuticals, Inc. (the "Company"), entered into a securies purchase agreement pursuant to which the Reporting Person agreed to acquire (i) an aggregate of 1,000,000 shares of the Company's Series C Convertible Preferred Stock (the "Series C Preferred Stock") at a price of $1.00 per share and (ii) an aggregate of 2,100,000 shares of the Company's Series D Convertible Preferred Stock (the "Series D Preferred Stock", and together with the Series C Preferred Stock, the "Preferred Stock") at a price of $1.00 per share. Each share of Series C Preferred Stock is convertible into 2.65 shares of the Company's Common Stock at any time. The initial closing took place on January 6, 2025, whereby the Reporting Person acquired 1,000,000 shares of Series C Preferred Stock for a total purchase price of $1,000,000.
- [F2]The shares of Series C Preferred Stock are convertible at the option of the Reporting Person for no additional consideration.
- [F3]The Series C Preferred Stock is perpetual and therefore has no expiration date.
- [F4]At a closing on February 6, 2025, the Reporting Person acquired 2,100,000 shares of Series D Preferred Stock for a total purchase price of $2,100,000. Each share of Series D Preferred Stock is convertible into 110 shares of the Company's Common Stock at any time.
- [F5]The shares of Series D Preferred Stock are convertible at the option of the Reporting Person for no additional consideration.
- [F6]The Series D Preferred Stock is perpetual and therefore has no expiration date.